-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Kymera Therapeutics, Raises Price Target to $103

Benzinga·12/16/2025 14:00:49
Listen to the news
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $70 to $103.